• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Precision Biosciences Inc (NQ: DTIL )

    9.941 +0.061 (+0.62%)
    Streaming Delayed Price Updated: 9:37 AM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 376
    Open 9.780
    Bid (Size) 9.780 (1)
    Ask (Size) 10.37 (1)
    Prev. Close 9.880
    Today's Range 9.780 - 9.941
    52wk Range 8.250 - 20.25
    Shares Outstanding 113,793,338
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces its Addition to the Russell Microcap® Index
    From Precision BioSciences, Inc.
    Via Business Wire

    Performance

    YTD
    -10.44%
    -10.44%
    1 Month
    +5.76%
    +5.76%
    3 Month
    +2.70%
    +2.70%
    6 Month
    -10.90%
    -10.90%
    1 Year
    -44.37%
    -44.37%

    More News

    Read More
    Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
    From Precision BioSciences, Inc.
    Via Business Wire
    Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Earnings Preview: Precision BioSciences
    Via Benzinga
    Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Participate in Upcoming June Investor Conferences
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Precision BioSciences, Inc.
    Via Business Wire
    DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Report First Quarter Results on May 13, 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
    From Precision BioSciences
    Via Business Wire
    Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
    From Precision BioSciences, Inc.
    Via Business Wire
    DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    Earnings Scheduled For March 27, 2024
    Via Benzinga
    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
    From Precision BioSciences
    Via Business Wire
    Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
    From Precision BioSciences, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.